Comparative Pharmacology
Head-to-head clinical analysis: IOHEXOL versus MD 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOHEXOL versus MD 50.
IOHEXOL vs MD-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ionic, water-soluble, iodinated contrast agent that increases the radiopacity of vascular structures and body cavities, allowing visualization during radiographic procedures. It does not bind to serum proteins and is rapidly distributed in extracellular fluid.
Iodinated radiographic contrast agent that attenuates X-rays due to its high iodine content, allowing visualization of vascular structures and organs during imaging. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Intravenous: 300-370 mg iodine/kg (0.3-0.37 mL/kg of 300 mg I/mL solution) for contrast imaging; typical range 15-150 mL per procedure depending on examination. Intra-arterial: Doses vary by procedure, typically 1-10 mL total. Do not exceed 3 mL/kg total dose.
300 mg intravenously every 12 hours.
None Documented
None Documented
Clinical Note
moderateIohexol + Metformin
"The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin."
Terminal elimination half-life approximately 2-3 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 30-60 hours, necessitating dose adjustment or avoidance.
Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Primarily renal via glomerular filtration; 90-100% of administered dose excreted unchanged in urine within 24 hours. Less than 2% excreted in feces. Biliary excretion negligible (<1%).
Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent